C12Q 1/485
Involving kinase
Official title: {involving kinase}
C12Q1/485 (Involving kinase) appears on 924 US grants and 1,834 published applications in this corpus.
Search patents in C12Q- Granted patents
- 924
- Published applications
- 1,834
- Assignees
- 771
- Inventors
- 3,553
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 5 | 0 |
| 1999 | 11 | 0 |
| 2000 | 12 | 0 |
| 2001 | 27 | 9 |
| 2002 | 17 | 64 |
| 2003 | 24 | 119 |
| 2004 | 29 | 78 |
| 2005 | 23 | 120 |
| 2006 | 39 | 105 |
| 2007 | 42 | 105 |
| 2008 | 45 | 104 |
| 2009 | 36 | 97 |
| 2010 | 52 | 100 |
| 2011 | 51 | 92 |
| 2012 | 45 | 72 |
| 2013 | 50 | 86 |
| 2014 | 50 | 91 |
| 2015 | 47 | 53 |
| 2016 | 39 | 63 |
| 2017 | 37 | 66 |
| 2018 | 46 | 49 |
| 2019 | 39 | 50 |
| 2020 | 34 | 41 |
| 2021 | 26 | 38 |
| 2022 | 16 | 37 |
| 2023 | 25 | 40 |
| 2024 | 14 | 56 |
| 2025 | 29 | 68 |
| 2026 | 13 | 31 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Gene conferring resistance to fungal pathogen29 Sep 2026US 12,747,450 B2KWS SAAT SE & Co. KGaA
- Medicament for improving or preventing symptoms relating to retina and/or light reception and method for screening for substance capable of improving or preventing symptoms relating to retina and/or light reception4 Aug 2026US 12,697,367 B2Osaka University
- Compositions, systems and methods for CRISPR-based enzyme optimization21 Jul 2026US 12,686,884 B210x Genomics, Inc.
- Chimeric DNA polymerase and application thereof7 Jul 2026US 12,674,147 B2Bgi Shenzhen
- Affinity labeling of DNA-linked ligands for high throughput ligand binding assays and the uses thereof30 Jun 2026US 12,669,497 B2Purdue Research Foundation
- Multi-target drug conjugate and use thereof for cancer treatment1 Oct 2026US 2026/0295061 A1Virginia Tech Intellectual Properties, Inc.
- A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer1 Oct 2026US 2026/0297088 A1Antares Therapeutics, Inc.
- Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors1 Oct 2026US 2026/0297646 A1Cardiff Oncology, Inc.
- Modification of Pseudouridine1 Oct 2026US 2026/0297649 A1Ludwig Institute for Cancer Research
- Reagent, kit, method for detecting adp, and use thereof24 Sep 2026US 2026/0286420 A1Neubo Apptech Co., Ltd.
Most cited
By later US patents
- Methods and apparatus for detecting nucleic acid polymorphisms185US 6,297,018 B1LJL BioSystems, Inc. · 2001
- Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments172US 7,294,468 B2Dana-Farber Cancer Institute, Inc. · 2007
- Enzyme substrate comprising a functional dye and associated technology and methods145US 8,092,784 B2Biotium, Inc. · 2012
- Assay methods and system133US 6,287,774 B1Caliper Technologies Corp. · 2001
- High affinity protein kinase inhibitors129US 6,383,790 B1Princeton University · 2002